Support NET Research
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading funder of neuroendocrine tumor (NET) research, having funded more than $30 million in research projects aimed at advancing improved treatments for neuroendocrine tumors. NETRF funds are solely provided by private donations from around the globe. There are many ways to support neuroendocrine tumor (NET) research, such a making a gift, volunteering, or hosting a fundraising event. We hope that the information you find on this page is helpful and will entice you to take the next step in getting involved with NETRF.
Your gift will fund world-class research, empower and educate NET survivors and families and bolster the field of NET research. Learn more about the impact of your gift .
COVID-19 — We Need Your Help
With COVID-19 affecting families around the globe, NETRF needs your support now more than ever. While we all adjust to different routines of school closings, working from home, and cancellation of activities, NET research must continue and not slow down. Giving online is a simple and safe way to make your donation today. Please visit our Give Now page to support NET research. Thank you!
For questions about making your gift, please contact Susan Payson, Chief Development Officer at firstname.lastname@example.org.
The latest in NET News
The fourteenth annual NETRF Research Symposium successfully concluded last month with over 300 registered virtual attendees participating from around the globe for the second year in a row. The meeting included nearly 60 talks and posters representing the cutting edge of NET research where investigators reported their latest data and discoveries to share and discuss with colleagues. This year posters were available for viewing over the three days preceding the two-day meeting, resulting in over 300 poster views and ample time for discussions. Over 95% of registrants attended the two-days of talks and live discussions while the recorded talks and posters were viewed by over 100 more attendees over the following week.
Dr. Thirlwell, the Mireille Gillings Professor of Cancer Genomics at the University of Exeter Medical School will assume the role in January of 2022. She is internationally renowned for advancing NET research, the clinical management of NETs and the integrated genomic analysis of cancer.
The phase 1a/1b clinical trial is being conducted in patients who have advanced small cell lung cancer, poorly differentiated neuroendocrine cancer, or pancreatic cancer. Satya Das, MD, MSCI, at Vanderbilt University Medical Center serves as principal investigator of the study, which is sponsored by the National Cancer Institute.